

ASX Announcement

Recce Pharmaceuticals Appoints James Graham as Chief Executive Officer

*Mr Graham has served as Executive Director of
Marketing and Business Development over the past five years*

Sydney Australia, 28 August 2020: Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing New Classes of Synthetic Anti-infectives, is pleased to announce the Board of Directors has unanimously appointed James Graham to the role of Chief Executive Officer.

Recce Pharmaceuticals Non-Executive Chairman Dr John Prendergast said, “James has demonstrated innate entrepreneurial and commercial skills that have been instrumental to the expansion of the Company. As James takes on his new role, the Board is confident in his ability to drive growth of the company’s expanding commercial opportunities and clinical initiatives. James’ appointment reflects his significant contributions to the business with an array of opportunities we are most excited about, now and into the future”.

Mr. Graham has a background in marketing, business development and commercialisation of early stage technologies. He will continue to serve as a Director on the Board.

Chief Executive Officer James Graham said, “Our business has long been a sum of all parts and is my privilege to lead such an outstanding team. With several critical near-term milestones pending, including the commencement of our Phase I clinical trial, a Western Australia Health Department Topical Burns Wound Study submission and SARS-CoV-2 antiviral studies active around the world - it’s a promising time for our business. I look forward to working with the team to build on the Company’s progress in the pursuit to unlock the full clinical and commercial potential in the time ahead.”

The key terms and conditions of Mr Graham’s appointment are set out in Attachment 1.

This announcement has been approved for release by Recce Pharmaceuticals Board.



ASX: RCE

Head Office: Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 T +61 (02) 8075 4585 F +61 (02) 8075 4584

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE[®] 327 and RECCE[®] 435, and RECCE[®] 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Patented lead candidate RECCE[®] 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Recce's new antibiotic compound, RECCE[®] 435, has been formulated for oral use.

The FDA has awarded RECCE[®] 327 *Qualified Infectious Disease Product* designation under the *Generating Antibiotic Initiatives Now* (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of RECCE[®] technologies targeting synergistic, unmet medical needs.

Executive Director

James Graham
Recce Pharmaceuticals Ltd
+61 (02) 8075 4585
james.graham@recce.com.au

Media and Investor Relations (AU)

Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)

Meredith Sosulski, PhD
LifeSci Communications
+1 929 469 3851
msosulski@lifescicomms.com

recce.com.au
ACN 124 849 065



Attachment 1 – Mr James Graham - Key Terms and Conditions of Employment

Effective Date	28 August 2020
Term	Appointment on an on-going basis subject to termination by either party.
Fixed Remuneration	\$300,000 per annum comprising base salary and superannuation
Short/Long Term Incentives	Any short or long term incentives will be considered by the Company's Nomination and Remuneration Committee, and will be announced to the market when any such incentive is put in place.
Termination and Notice	<p>Mr Graham may terminate the Employment at any time and for any reason by giving to the Company 2 months' notice in writing.</p> <p>The Company may terminate the Employment at any time and for any reason by giving Mr Graham 6 months' notice in writing.</p>



Executive Director

James Graham
Recce Pharmaceuticals Ltd
+61 (02) 8075 4585
james.graham@recce.com.au

Media and Investor Relations (AU)

Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)

Meredith Sosulski, PhD
LifeSci Communications
+1 929 469 3851
msosulski@lifescicomms.com